Autres langues Sutro Biopharma, Inc.

Actions

STRO

US8693671021

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
3,52 ^USD	+2,92 %		-6,63 %	-17,95 %

03/04	SUTRO BIOPHARMA, INC. : Piper Sandler maintient sa recommandation à l'achat	ZM
03/04	SUTRO BIOPHARMA, INC. : Truist Securities réitère son opinion positive sur le titre	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sutro Biopharma : Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”	04/04
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering	02/04
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	02/04
Ipsen : accord de licence mondiale avec Sutro Biopharma	02/04
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	02/04
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	26/03
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones	25/03
Sutro Biopharma to Participate in Upcoming Investor Conferences	06/02
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC	04/01
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC	04/01
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR-targeted ADC, on January 4, 2024	15/12
Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from NASDAQ Biotechnology Index	15/12
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024	14/12
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed, Refractory CBF/GLIS Presented at ASH 2023	12/12
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	11/12
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	11/12
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit	04/12
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma; Sutro Shares Jump Premarket	28/11
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma	27/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Sutro Biopharma, Inc.

Actions

STRO

US8693671021

Autres langues

Filtres